12 Results

People

  1. Postow
    Postow
  2. Wolchok
    Wolchok
  3. Callahan
    Callahan
  4. Panageas
    Panageas
  5. Chapman
    Chapman
  6. Hellmann
    Hellmann
  7. Budhu
    Budhu
  8. Hollmann
    Hollmann
  9. Liu
    Liu
  10. Li
    Li

Groups

  1. Department of Medicine (12)
  2. GSK Faculty (12)
  3. Melanoma Disease Management Team (12)
  4. Melanoma and Immunotherapeutics Service (12)
  5. Solid Tumor Oncology Division (12)
  6. Biostatistics Service (4)
  7. Epidemiology and Biostatistics (4)
  8. Population Sciences Research Program (4)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  10. Hematologic Malignancies, Division of (3)
  1. "cancer immunotherapy"
  2. "GSK Faculty"
  3. "Department of Medicine"
  4. "Michael Postow"
Formats
  1. Journal Article (12)
Groups
  1. Department of Medicine (12)
  2. GSK Faculty (12)
  3. Melanoma Disease Management Team (12)
  4. Melanoma and Immunotherapeutics Service (12)
  5. Solid Tumor Oncology Division (12)
  6. Biostatistics Service (4)

More Groups

People
  1. Michael Postow (12)
  2. Jedd Wolchok (11)
  3. Margaret Callahan (6)
  4. Katherine Panageas (4)
  5. Matthew Hellmann (3)
  6. Paul Chapman (3)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (2)
  4. 2019 (1)
  5. 2018 (1)
  6. 2017 (1)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (2)
  2. American Journal of Clinical Oncology (1)
  3. Annals of Surgical Oncology (1)
  4. Cancer (1)
  5. Cancer Cell (1)
  6. Clinics in Dermatology (1)

More Publications

Publishers
  1. Biomed Central Ltd (2)
  2. Lippincott Williams & Wilkins (2)
  3. American Association for the Advancement of Science (1)
  4. American Society of Clinical Oncology (1)
  5. Cell Press (1)
  6. Elsevier Inc. (1)

More Publishers

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies
    Journal Article

    Bander, E. D.; Yuan, M.; Carnevale, J. A.; Reiner, A. S.; Panageas, K. S.; Postow, M. A.; Tabar, V.; Moss, N. S.
    Cancer (2021)

    Fulltext@MSK | Save
  • Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade
    Journal Article

    Bello, D. M.; Panageas, K. S.; Hollmann, T.; Shoushtari, A. N.; Momtaz, P.; Chapman, P. B.; Postow, M. A.; Callahan, M. K.; Wolchok, J. D.; Brady, M. S.; more...
    Annals of Surgical Oncology (2020)

    Fulltext@MSK | Save
  • Intravitreous cutaneous metastatic melanoma in the era of checkpoint inhibition: Unmasking and masquerading
    Journal Article

    Francis, J. H.; Berry, D.; Abramson, D. H.; Barker, C. A.; Bergstrom, C.; Demirci, H.; Engelbert, M.; Grossniklaus, H.; Hubbard, B.; Iacob, C. E.; more...
    Ophthalmology (2020)

    Fulltext@MSK | Save
  • Rational design of anti-GITR-based combination immunotherapy
    Journal Article

    Zappasodi, R.; Sirard, C.; Li, Y.; Budhu, S.; Abu-Akeel, M.; Liu, C.; Yang, X.; Zhong, H.; Newman, W.; Qi, J.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Non-conventional inhibitory CD4(+)Foxp3(−)PD-1(hi) T cells as a biomarker of immune checkpoint blockade activity
    Journal Article

    Zappasodi, R.; Budhu, S.; Hellmann, M. D.; Postow, M. A.; Senbabaoglu, Y.; Manne, S.; Gasmi, B.; Liu, C.; Zhong, H.; Li, Y.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials
    Journal Article

    Schadendorf, D.; Wolchok, J. D.; Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Chesney, J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
    Journal Article

    Lesokhin, A. M.; Callahan, M. K.; Postow, M. A.; Wolchok, J. D.
    Science Translational Medicine (2015)

    Fulltext@MSK | Save
  • Immune-priming of the tumor microenvironment by radiotherapy: Rationale for combination with immunotherapy to improve anticancer efficacy
    Journal Article

    Shahabi, V.; Postow, M. A.; Tuck, D.; Wolchok, J. D.
    American Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Opportunistic infections in patients treated with immunotherapy for cancer
    Journal Article

    Kyi, C.; Hellmann, M. D.; Wolchok, J. D.; Chapman, P. B.; Postow, M. A.
    Journal for ImmunoTherapy of Cancer (2014)

    Fulltext@MSK | Save